In a major development, Lupin Ltd announced a partnership with US-headquartered global biopharmaceutical player, AbbVie Inc for developing novel oncology drug to treat haematological cancer. Following the partnership, AbbVie gains exclusive global rights to develop and commercialise Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitors.
Under the terms of the agreement, AbbVie will pay Lupin an upfront payment of $30 million for an exclusive licence to the program. Upon successful completion of regulatory, development and commercial milestones, Lupin is eligible to receive total milestone payments of up to $947 million. Additionally, Lupin will be entitled to receive a double-digit royalty on the sales of the product and will retain commercial rights to the program in India.
MALT-1 is a protein involved in T-cell and B-cell lymphocyte activation and AbbVie intends to pursue development across a range of haematological cancers, many with limited current treatment options.